60 acast.com Behind the Breakthroughs https://shows.acast.com/behind-the-breakthroughs-by-inside-precision-medicine en Inside Precision Medicine precision medicine,personalized therapeutics,drug discovery and development Inside Precision Medicine Join host Jonathan D. Grinstein, PhD, North American Editor for Inside Precision Medicine, as he uncovers the stories behind the pioneers driving the precision medicine revolution. Behind the Breakthroughs features candid interviews with seasoned veterans and rising stars, exploring their origin stories and groundbreaking contributions advancing the frontiers of patient diagnosis, treatment, and care.


In every episode, Jonathan goes beyond the science, diving deep into the personal and professional journeys of those striving to make these incredible new therapies more equitable and accessible globally. You'll discover how emerging technologies in molecular diagnostics, next-generation sequencing, genetic medicines (e.g., cell and gene therapies), and AI/ML are transforming treatment and bringing precision medicine closer to the forefront of healthcare. Whether you’re a researcher at a large pharma company or small biotech startup, a clinician at a major health system or community setting, a laboratory technician in the clinic or academia, an investor at a premier or venture capital firm, or just interested in the latest in medicine and healthcare, these interviews will inspire and inform you about personalized medicine's future.

Hosted on Acast. See acast.com/privacy for more information.

]]> Join host Jonathan D. Grinstein, PhD, North American Editor for Inside Precision Medicine, as he uncovers the stories behind the pioneers driving the precision medicine revolution. Behind the Breakthroughs features candid interviews with seasoned veterans and rising stars, exploring their origin stories and groundbreaking contributions advancing the frontiers of patient diagnosis, treatment, and care.


In every episode, Jonathan goes beyond the science, diving deep into the personal and professional journeys of those striving to make these incredible new therapies more equitable and accessible globally. You'll discover how emerging technologies in molecular diagnostics, next-generation sequencing, genetic medicines (e.g., cell and gene therapies), and AI/ML are transforming treatment and bringing precision medicine closer to the forefront of healthcare. Whether you’re a researcher at a large pharma company or small biotech startup, a clinician at a major health system or community setting, a laboratory technician in the clinic or academia, an investor at a premier or venture capital firm, or just interested in the latest in medicine and healthcare, these interviews will inspire and inform you about personalized medicine's future.

Hosted on Acast. See acast.com/privacy for more information.

]]> false Inside Precision Medicine info+67105af848726944170ab1fe@mg-eu.acast.com 67105af848726944170ab1fe behind-the-breakthroughs-by-inside-precision-medicine episodic https://assets.pippa.io/shows/67105af848726944170ab1fe/1729176633209-4c042f7e-c9b1-44c7-b2f0-3d36b4c78148.jpeg https://shows.acast.com/behind-the-breakthroughs-by-inside-precision-medicine Behind the Breakthroughs Molly Gibson: Superintelligence and the Future of Drug Development Molly Gibson: Superintelligence and the Future of Drug Development Wed, 08 Apr 2026 07:01:00 GMT 51:25 69d4b12707bc2cbfc701e19e false https://shows.acast.com/behind-the-breakthroughs-by-inside-precision-medicine/episodes/molly-gibson-superintelligence-and-the-future-of-drug-develo 69d4b12707bc2cbfc701e19e 67105af848726944170ab1fe molly-gibson-superintelligence-and-the-future-of-drug-develo Origination Partner at Flagship Pioneering and Co-founder of Generate:Biomedicines, Lila Biosciences, and Expedition Medicines full 39 As an Origination Partner at Flagship Pioneering, Molly Gibson, PhD, co-founded her first company, Generate:Biomedicines, in 2018, where she made her mark by developing models that design novel proteins—work that has already led to a Phase 3 asthma drug. Since then, she has gone on to co-found two additional companies: Expedition Medicines and Lila Biosciences. In this episode, Molly explains why the anticipated boom in AI-guided drug development hasn’t fully materialized and how she’s tackling the challenge by modeling complex chemistry to synthesize novel small molecules at Expedition Medicines. She also discusses building "superintelligence" and closed-loop systems in which AI can autonomously generate, test, and refine scientific ideas at Lila Biosciences.



Produced and hosted by Jonathan D. Grinstein, PhD

Audio mixed and mastered by Erick Ziegler

Brought to you by Inside Precision Medicine (SAGE Publishing)

Hosted on Acast. See acast.com/privacy for more information.

]]> As an Origination Partner at Flagship Pioneering, Molly Gibson, PhD, co-founded her first company, Generate:Biomedicines, in 2018, where she made her mark by developing models that design novel proteins—work that has already led to a Phase 3 asthma drug. Since then, she has gone on to co-found two additional companies: Expedition Medicines and Lila Biosciences. In this episode, Molly explains why the anticipated boom in AI-guided drug development hasn’t fully materialized and how she’s tackling the challenge by modeling complex chemistry to synthesize novel small molecules at Expedition Medicines. She also discusses building "superintelligence" and closed-loop systems in which AI can autonomously generate, test, and refine scientific ideas at Lila Biosciences.



Produced and hosted by Jonathan D. Grinstein, PhD

Audio mixed and mastered by Erick Ziegler

Brought to you by Inside Precision Medicine (SAGE Publishing)

Hosted on Acast. See acast.com/privacy for more information.

]]> Mike Curtis: Pig Organs as a Bridge to Human Transplants Mike Curtis: Pig Organs as a Bridge to Human Transplants Wed, 25 Mar 2026 07:01:00 GMT 52:22 69c1ce3a1a160b44dbcc0ce8 false https://shows.acast.com/behind-the-breakthroughs-by-inside-precision-medicine/episodes/mike-curtis-pig-organs-as-a-bridge-to-human-transplants 69c1ce3a1a160b44dbcc0ce8 67105af848726944170ab1fe mike-curtis-pig-organs-as-a-bridge-to-human-transplants President and CEO of eGenesis full 38 Xenotransplantation has long been a scientifically promising but ethically complex field, overshadowed by its limited practicality despite the growing shortage of transplantable organs and the urgent needs of patients. Recent breakthroughs, including genetically modified pig heart transplants in 2022 and 2023, have demonstrated its feasibility, marking a turning point even though long-term survival has not yet been achieved. In this episode of Behind the Breakthroughs, Mike Curtis, PhD, President and CEO of eGenesis, explains how the company is building on this success to advance xenotransplantation as a scalable clinical strategy, emphasizing that even temporary extensions of life—such as a recent nine-month kidney transplant case—can provide meaningful outcomes and bridge patients to future treatments.


Produced and hosted by Jonathan D. Grinstein, PhD

Audio mixed and mastered by Erick Ziegler

Brought to you by Inside Precision Medicine (SAGE Publishing)


Hosted on Acast. See acast.com/privacy for more information.

]]> Xenotransplantation has long been a scientifically promising but ethically complex field, overshadowed by its limited practicality despite the growing shortage of transplantable organs and the urgent needs of patients. Recent breakthroughs, including genetically modified pig heart transplants in 2022 and 2023, have demonstrated its feasibility, marking a turning point even though long-term survival has not yet been achieved. In this episode of Behind the Breakthroughs, Mike Curtis, PhD, President and CEO of eGenesis, explains how the company is building on this success to advance xenotransplantation as a scalable clinical strategy, emphasizing that even temporary extensions of life—such as a recent nine-month kidney transplant case—can provide meaningful outcomes and bridge patients to future treatments.


Produced and hosted by Jonathan D. Grinstein, PhD

Audio mixed and mastered by Erick Ziegler

Brought to you by Inside Precision Medicine (SAGE Publishing)


Hosted on Acast. See acast.com/privacy for more information.

]]> Markus Warmuth: Eliminating Pathogenic Proteins with Molecular Glue Degraders Markus Warmuth: Eliminating Pathogenic Proteins with Molecular Glue Degraders Wed, 11 Mar 2026 07:01:00 GMT 48:23 69ab36ebb49eecc0b7c39b2a false https://shows.acast.com/behind-the-breakthroughs-by-inside-precision-medicine/episodes/markus-warmuth-eliminating-pathogenic-proteins-with-molecula 69ab36ebb49eecc0b7c39b2a 67105af848726944170ab1fe markus-warmuth-eliminating-pathogenic-proteins-with-molecula full 37

Traditional drugs usually inhibit specific protein sites, but many disease-causing proteins lack accessible or unique motifs, leaving them “undruggable.” Targeted Small-molecule drugs have long been the quiet workhorses of modern medicine, slipping inside cells to target disease-driving proteins, even as biologics, immunotherapies, and genetic medicines have taken center stage in recent years. Yet thousands of disease-related proteins remain “undruggable” because they lack the structural pockets needed for traditional inhibitors to bind. In this episode, Markus Warmuth, MD, CEO of Monte Rosa Therapeutics, explains how molecular glue degraders harness the cell’s protein-disposal machinery to eliminate harmful proteins entirely, and how the company’s QUEEN discovery platform is advancing new therapies in cancer and autoimmune disease.



Produced and hosted by Jonathan D. Grinstein, PhD

Audio mixed and mastered by Erick Ziegler

Brought to you by Inside Precision Medicine (SAGE Publishing)

Hosted on Acast. See acast.com/privacy for more information.

]]>

Traditional drugs usually inhibit specific protein sites, but many disease-causing proteins lack accessible or unique motifs, leaving them “undruggable.” Targeted Small-molecule drugs have long been the quiet workhorses of modern medicine, slipping inside cells to target disease-driving proteins, even as biologics, immunotherapies, and genetic medicines have taken center stage in recent years. Yet thousands of disease-related proteins remain “undruggable” because they lack the structural pockets needed for traditional inhibitors to bind. In this episode, Markus Warmuth, MD, CEO of Monte Rosa Therapeutics, explains how molecular glue degraders harness the cell’s protein-disposal machinery to eliminate harmful proteins entirely, and how the company’s QUEEN discovery platform is advancing new therapies in cancer and autoimmune disease.



Produced and hosted by Jonathan D. Grinstein, PhD

Audio mixed and mastered by Erick Ziegler

Brought to you by Inside Precision Medicine (SAGE Publishing)

Hosted on Acast. See acast.com/privacy for more information.

]]> Alicia Zhou: The Dark Matter for Cancer Immunotherapy Translation Alicia Zhou: The Dark Matter for Cancer Immunotherapy Translation Wed, 25 Feb 2026 08:01:00 GMT 57:26 699d2905e3f0d89ce2fb1230 false https://shows.acast.com/behind-the-breakthroughs-by-inside-precision-medicine/episodes/alicia-zhou-the-dark-matter-for-cancer-immunotherapy-transla 699d2905e3f0d89ce2fb1230 67105af848726944170ab1fe alicia-zhou-the-dark-matter-for-cancer-immunotherapy-transla CEO at Cancer Research Institute (CRI) full 36 Cancer Research Institute CEO Alicia Zhou, PhD, traces her path from teenage lab technician to leader in cancer immunotherapy. Trained at MIT and Dana-Farber, she worked on The Cancer Genome Atlas before moving to industry at Color Genomics, expanding access to clinical sequencing. Zhou champions applying advanced genomics to immunotherapy through CRI’s Discovery Engine, an open dataset mapping tumor–immune interactions. She argues nonprofits uniquely fund shared infrastructure and standardization efforts. By supporting collaboration, young scientists, and patient resources, Zhou aims to accelerate breakthroughs and ultimately make cancer solvable.


Produced and hosted by Jonathan D. Grinstein, PhD

Audio mixed and mastered by Erick Ziegler

Brought to you by Inside Precision Medicine (SAGE Publishing)

Hosted on Acast. See acast.com/privacy for more information.

]]> Cancer Research Institute CEO Alicia Zhou, PhD, traces her path from teenage lab technician to leader in cancer immunotherapy. Trained at MIT and Dana-Farber, she worked on The Cancer Genome Atlas before moving to industry at Color Genomics, expanding access to clinical sequencing. Zhou champions applying advanced genomics to immunotherapy through CRI’s Discovery Engine, an open dataset mapping tumor–immune interactions. She argues nonprofits uniquely fund shared infrastructure and standardization efforts. By supporting collaboration, young scientists, and patient resources, Zhou aims to accelerate breakthroughs and ultimately make cancer solvable.


Produced and hosted by Jonathan D. Grinstein, PhD

Audio mixed and mastered by Erick Ziegler

Brought to you by Inside Precision Medicine (SAGE Publishing)

Hosted on Acast. See acast.com/privacy for more information.

]]> Brad Ringeisen: CRISPR for Disease Elimination and Humanitarian Solutions Brad Ringeisen: CRISPR for Disease Elimination and Humanitarian Solutions Wed, 11 Feb 2026 08:01:00 GMT 57:39 698b76520581faffc7699a4e false https://shows.acast.com/behind-the-breakthroughs-by-inside-precision-medicine/episodes/brad-ringeisen-crispr-for-disease-elimination-and-humanitari 698b76520581faffc7699a4e 67105af848726944170ab1fe brad-ringeisen-crispr-for-disease-elimination-and-humanitari Executive Director at Innovative Genomics Institute (IGI) full 35 CRISPR has crossed a turning point, evolving from an experimental tool into a platform delivering FDA-approved therapies and on-demand patient treatments that correct disease at its source. Brad Ringeisen, a former DARPA office director and leader at the Innovative Genomics Institute (IGI), has been at the center of that transition, helping guide CRISPR from early promise toward scalable clinical impact. Ringeisen discusses in this episode how he is collaborating with CRISPR pioneer and Nobel Prize winner Jennifer Doudna, PhD, at the IGI to address rare, complex, and underserved diseases, going beyond isolated successes. Accessibility, durability, and worldwide benefit, Ringeisen believes, will be the real indicators of CRISPR's success.


Produced and hosted by Jonathan D. Grinstein, PhD

Audio mixed and mastered by Erick Ziegler

Brought to you by Inside Precision Medicine (SAGE Publishing)

Hosted on Acast. See acast.com/privacy for more information.

]]> CRISPR has crossed a turning point, evolving from an experimental tool into a platform delivering FDA-approved therapies and on-demand patient treatments that correct disease at its source. Brad Ringeisen, a former DARPA office director and leader at the Innovative Genomics Institute (IGI), has been at the center of that transition, helping guide CRISPR from early promise toward scalable clinical impact. Ringeisen discusses in this episode how he is collaborating with CRISPR pioneer and Nobel Prize winner Jennifer Doudna, PhD, at the IGI to address rare, complex, and underserved diseases, going beyond isolated successes. Accessibility, durability, and worldwide benefit, Ringeisen believes, will be the real indicators of CRISPR's success.


Produced and hosted by Jonathan D. Grinstein, PhD

Audio mixed and mastered by Erick Ziegler

Brought to you by Inside Precision Medicine (SAGE Publishing)

Hosted on Acast. See acast.com/privacy for more information.

]]> Zachary Roberts: Building a Viable Off-the-Shelf CAR T Zachary Roberts: Building a Viable Off-the-Shelf CAR T Wed, 28 Jan 2026 08:01:00 GMT 56:14 6978f145e23c68f310a991a6 false https://shows.acast.com/behind-the-breakthroughs-by-inside-precision-medicine/episodes/zachary-roberts-building-a-viable-off-the-shelf-car-t 6978f145e23c68f310a991a6 67105af848726944170ab1fe zachary-roberts-building-a-viable-off-the-shelf-car-t full 34 Cancer immunotherapy evolved through decades of research, with watershed moments like checkpoint inhibitor approvals and the first CAR T trial results reshaping expectations. For Zachary Roberts, MD, PhD, witnessing CAR T-induced remissions as a Mass General resident convinced him of the field’s future and drew him from academia into drug development. Now as CMO and EVP of R&D at Allogene Therapeutics, he’s focused on the next inflection point: transforming CAR T into scalable, off-the-shelf therapies that could broaden access and extend impact beyond cancer to autoimmune disease.


Produced and hosted by Jonathan D. Grinstein, PhD

Audio mixed and mastered by Erick Ziegler

Brought to you by Inside Precision Medicine (SAGE Publishing)

Hosted on Acast. See acast.com/privacy for more information.

]]> Cancer immunotherapy evolved through decades of research, with watershed moments like checkpoint inhibitor approvals and the first CAR T trial results reshaping expectations. For Zachary Roberts, MD, PhD, witnessing CAR T-induced remissions as a Mass General resident convinced him of the field’s future and drew him from academia into drug development. Now as CMO and EVP of R&D at Allogene Therapeutics, he’s focused on the next inflection point: transforming CAR T into scalable, off-the-shelf therapies that could broaden access and extend impact beyond cancer to autoimmune disease.


Produced and hosted by Jonathan D. Grinstein, PhD

Audio mixed and mastered by Erick Ziegler

Brought to you by Inside Precision Medicine (SAGE Publishing)

Hosted on Acast. See acast.com/privacy for more information.

]]> Boyang Wang: Organ Swaps and Mass Preventative Gene Therapy to Extend Lifespan Boyang Wang: Organ Swaps and Mass Preventative Gene Therapy to Extend Lifespan Wed, 07 Jan 2026 08:01:00 GMT 54:10 695d477fd1ba84fb8f019f7f false https://shows.acast.com/behind-the-breakthroughs-by-inside-precision-medicine/episodes/organ-swaps-and-mass-preventative-gene-therapy-to-extend-lif 695d477fd1ba84fb8f019f7f 67105af848726944170ab1fe organ-swaps-and-mass-preventative-gene-therapy-to-extend-lif Founder of Immortal Dragons full 33 Geroscience sits between hype and skepticism, with headlines swinging from dubious mouse-life supplements to ethically distant fantasies like organ or head transplants. Yet precision medicine has been turning science fiction into reality. Today’s guest, Boyang Wang, thinks lifespan extension is next. Founder of Singapore-based Immortal Dragons, he backs longevity companies—from organ printing to preventive gene therapies. A former computer scientist and tech entrepreneur, Wang now runs a $40M fund supporting underfunded bets on healthspan and aging.


Produced and hosted by Jonathan D. Grinstein, PhD

Audio mixed and mastered by Erick Ziegler

Brought to you by Inside Precision Medicine (SAGE Publishing)

Hosted on Acast. See acast.com/privacy for more information.

]]> Geroscience sits between hype and skepticism, with headlines swinging from dubious mouse-life supplements to ethically distant fantasies like organ or head transplants. Yet precision medicine has been turning science fiction into reality. Today’s guest, Boyang Wang, thinks lifespan extension is next. Founder of Singapore-based Immortal Dragons, he backs longevity companies—from organ printing to preventive gene therapies. A former computer scientist and tech entrepreneur, Wang now runs a $40M fund supporting underfunded bets on healthspan and aging.


Produced and hosted by Jonathan D. Grinstein, PhD

Audio mixed and mastered by Erick Ziegler

Brought to you by Inside Precision Medicine (SAGE Publishing)

Hosted on Acast. See acast.com/privacy for more information.

]]> Year In Review: My Personal Genomics Journey Redux Year In Review: My Personal Genomics Journey Redux Wed, 17 Dec 2025 08:01:00 GMT 42:15 69419524891c3619dc885cac false https://shows.acast.com/behind-the-breakthroughs-by-inside-precision-medicine/episodes/year-in-review-my-personal-genomics-journey-redux 69419524891c3619dc885cac 67105af848726944170ab1fe year-in-review-my-personal-genomics-journey-redux full 32 In this episode, I’m joined by Kevin Davies, PhD, Director of Professional Media Content Development at Sage Publications and acclaimed author of Editing Humanity, one of Jennifer Doudna’s favorite books on CRISPR. We explore key themes in precision medicine in 2025, including personal genomics, gene editing, and clinical impact. The discussion centers on my personal genomic testing series, major gene-editing advances, and emerging debates around embryo selection and IVF-based genomics heading into 2026.


Produced and hosted by Jonathan D. Grinstein, PhD

Audio mixed and mastered by Erick Ziegler

Brought to you by Inside Precision Medicine (SAGE Publishing)

Hosted on Acast. See acast.com/privacy for more information.

]]> In this episode, I’m joined by Kevin Davies, PhD, Director of Professional Media Content Development at Sage Publications and acclaimed author of Editing Humanity, one of Jennifer Doudna’s favorite books on CRISPR. We explore key themes in precision medicine in 2025, including personal genomics, gene editing, and clinical impact. The discussion centers on my personal genomic testing series, major gene-editing advances, and emerging debates around embryo selection and IVF-based genomics heading into 2026.


Produced and hosted by Jonathan D. Grinstein, PhD

Audio mixed and mastered by Erick Ziegler

Brought to you by Inside Precision Medicine (SAGE Publishing)

Hosted on Acast. See acast.com/privacy for more information.

]]> David Fischel: Surgical Robotics for Superhuman and Remote Operations David Fischel: Surgical Robotics for Superhuman and Remote Operations Wed, 03 Dec 2025 08:01:00 GMT 58:50 692e4a6efcd33ebbab903a22 false https://shows.acast.com/behind-the-breakthroughs-by-inside-precision-medicine/episodes/david-fischel-surgical-robotics-for-superhuman-and-remote-op 692e4a6efcd33ebbab903a22 67105af848726944170ab1fe david-fischel-surgical-robotics-for-superhuman-and-remote-op CEO at Stereotaxis full 31 Precision medicine isn’t just molecular—it’s anatomical. Even as gene editing advances, many conditions still demand exquisitely targeted surgical care. That’s the world envisioned by Stereotaxis CEO David Fischel, where operations become remote, cockpit-guided missions. Using magnetic “invisible fingers,” surgeons steer ultra-soft catheters with sub-millimeter precision through fragile vessels. After two decades and 170,000 patients, Stereotaxis has reshaped cardiac procedures into robotic navigation—bridging genomics, anatomy, and the future of intervention.


Produced and hosted by Jonathan D. Grinstein, PhD

Audio mixed and mastered by Erick Ziegler

Brought to you by Inside Precision Medicine (SAGE Publishing)

Hosted on Acast. See acast.com/privacy for more information.

]]> Precision medicine isn’t just molecular—it’s anatomical. Even as gene editing advances, many conditions still demand exquisitely targeted surgical care. That’s the world envisioned by Stereotaxis CEO David Fischel, where operations become remote, cockpit-guided missions. Using magnetic “invisible fingers,” surgeons steer ultra-soft catheters with sub-millimeter precision through fragile vessels. After two decades and 170,000 patients, Stereotaxis has reshaped cardiac procedures into robotic navigation—bridging genomics, anatomy, and the future of intervention.


Produced and hosted by Jonathan D. Grinstein, PhD

Audio mixed and mastered by Erick Ziegler

Brought to you by Inside Precision Medicine (SAGE Publishing)

Hosted on Acast. See acast.com/privacy for more information.

]]> Katherine Stueland: The Diagnostic Odyssey Era Ends with Early Genomics Katherine Stueland: The Diagnostic Odyssey Era Ends with Early Genomics Wed, 19 Nov 2025 08:01:00 GMT 54:06 691baf24b9580981598b479f false https://shows.acast.com/behind-the-breakthroughs-by-inside-precision-medicine/episodes/katherine-stueland 691baf24b9580981598b479f 67105af848726944170ab1fe katherine-stueland CEO at GeneDx full 30 Katherine Stueland’s early advocacy—raising money for genetic disease research as a child—shaped her belief that genomic insight can change lives. As CEO of GeneDx, she has refocused the company on high-need conditions, tripled sequencing capacity, delivered more than 750,000 exomes and genomes, and returned the company to profitability. She highlights the power of combining sequencing with the Infinity database and champions newborn screening, all guided by a core principle: genomic access should reach every family.


Produced and hosted by Jonathan D. Grinstein, PhD

Audio mixed and mastered by Erick Ziegler

Brought to you by Inside Precision Medicine (SAGE Publishing)

Hosted on Acast. See acast.com/privacy for more information.

]]> Katherine Stueland’s early advocacy—raising money for genetic disease research as a child—shaped her belief that genomic insight can change lives. As CEO of GeneDx, she has refocused the company on high-need conditions, tripled sequencing capacity, delivered more than 750,000 exomes and genomes, and returned the company to profitability. She highlights the power of combining sequencing with the Infinity database and champions newborn screening, all guided by a core principle: genomic access should reach every family.


Produced and hosted by Jonathan D. Grinstein, PhD

Audio mixed and mastered by Erick Ziegler

Brought to you by Inside Precision Medicine (SAGE Publishing)

Hosted on Acast. See acast.com/privacy for more information.

]]> Rahul Gupta: Can Biotech Fix U.S. Healthcare Faster than Policy? Rahul Gupta: Can Biotech Fix U.S. Healthcare Faster than Policy? Wed, 12 Nov 2025 08:01:00 GMT 54:37 69112e58f273d64d0bb96679 false https://shows.acast.com/behind-the-breakthroughs-by-inside-precision-medicine/episodes/rahul-gupta-can-biotech-fix-us-healthcare-faster-than-policy 69112e58f273d64d0bb96679 67105af848726944170ab1fe rahul-gupta-can-biotech-fix-us-healthcare-faster-than-policy full 29 When Rahul Gupta, MD, MPH, stepped down in January 2025 as Director of the White House Office of National Drug Control Policy, he closed a historic chapter as the first physician and first immigrant to serve as America’s “drug czar.” He steered national drug policy toward a public-health approach, advancing harm reduction, expanding naloxone access, and reframing addiction as a treatable condition amid the deadliest years of the fentanyl crisis. Now, as President of GATC Health, Gupta is channeling his experience into biotechnology and AI, seeking to accelerate drug discovery and use data-driven tools to outpace the slow machinery of government.


Produced and hosted by Jonathan D. Grinstein, PhD

Audio mixed and mastered by Erick Ziegler

Brought to you by Inside Precision Medicine (SAGE Publishing)

Hosted on Acast. See acast.com/privacy for more information.

]]> When Rahul Gupta, MD, MPH, stepped down in January 2025 as Director of the White House Office of National Drug Control Policy, he closed a historic chapter as the first physician and first immigrant to serve as America’s “drug czar.” He steered national drug policy toward a public-health approach, advancing harm reduction, expanding naloxone access, and reframing addiction as a treatable condition amid the deadliest years of the fentanyl crisis. Now, as President of GATC Health, Gupta is channeling his experience into biotechnology and AI, seeking to accelerate drug discovery and use data-driven tools to outpace the slow machinery of government.


Produced and hosted by Jonathan D. Grinstein, PhD

Audio mixed and mastered by Erick Ziegler

Brought to you by Inside Precision Medicine (SAGE Publishing)

Hosted on Acast. See acast.com/privacy for more information.

]]> Michael Langer: Biotech Investing in the Data Age Michael Langer: Biotech Investing in the Data Age Wed, 29 Oct 2025 07:01:00 GMT 49:01 69001bb9594b659111a8f9fb false https://shows.acast.com/behind-the-breakthroughs-by-inside-precision-medicine/episodes/michael-langer-biotech-investing-in-the-data-age 69001bb9594b659111a8f9fb 67105af848726944170ab1fe michael-langer-biotech-investing-in-the-data-age Co-founder and Managing Partner at T.Rx Capital full 28 If you work in biotech, the name Langer likely rings a bell. Robert Langer—the MIT legend behind Moderna and dozens of biotech startups—has become synonymous with innovation. Now, a new Langer is stepping forward. Michael Langer, Robert’s son, represents a new generation of investors rethinking biotech in the age of AI and data. Rather than chasing hype, he’s applying lessons from a lifetime around scientists to build a more disciplined, informed investment philosophy. As co-founder of T.Rx Capital, he’s helping shape the next phase of tech-enabled biotech—and exploring what truly drives success in precision medicine.


Produced and hosted by Jonathan D. Grinstein, PhD

Audio mixed and mastered by David Mosely

Brought to you by Inside Precision Medicine (SAGE Publishing)

Hosted on Acast. See acast.com/privacy for more information.

]]> If you work in biotech, the name Langer likely rings a bell. Robert Langer—the MIT legend behind Moderna and dozens of biotech startups—has become synonymous with innovation. Now, a new Langer is stepping forward. Michael Langer, Robert’s son, represents a new generation of investors rethinking biotech in the age of AI and data. Rather than chasing hype, he’s applying lessons from a lifetime around scientists to build a more disciplined, informed investment philosophy. As co-founder of T.Rx Capital, he’s helping shape the next phase of tech-enabled biotech—and exploring what truly drives success in precision medicine.


Produced and hosted by Jonathan D. Grinstein, PhD

Audio mixed and mastered by David Mosely

Brought to you by Inside Precision Medicine (SAGE Publishing)

Hosted on Acast. See acast.com/privacy for more information.

]]> Vanessa Almendro-Navarro: Baby KJ and The Promise of Custom Gene Editing Vanessa Almendro-Navarro: Baby KJ and The Promise of Custom Gene Editing Wed, 15 Oct 2025 07:01:00 GMT 1:00:03 68e49cdcf1f51e6179d6f104 false https://shows.acast.com/behind-the-breakthroughs-by-inside-precision-medicine/episodes/vanessa-almendro-navarro-bespoke-gene-editing-as-the-new-cli 68e49cdcf1f51e6179d6f104 67105af848726944170ab1fe vanessa-almendro-navarro-bespoke-gene-editing-as-the-new-cli Vice President of Science and Technology at Danaher Corporation full 27 When a rare genetic mutation left baby KJ without any treatment options, scientists and regulators confronted a profound ethical question: should medicine move fast enough to save a single child? For geneticist Vanessa Almendro-Navarro, PhD, KJ’s case represented both an urgent humanitarian mission and a glimpse into the future of personalized medicine. In this interview, she explains how her team created a bespoke gene-editing therapy for KJ, what it reveals about the rise of one-patient medicines, and how unprecedented collaboration is reshaping the boundaries of science and ethics.


Produced and hosted by Jonathan D. Grinstein, PhD

Audio mixed and mastered by David Mosely

Brought to you by Inside Precision Medicine (SAGE Publishing)


Hosted on Acast. See acast.com/privacy for more information.

]]> When a rare genetic mutation left baby KJ without any treatment options, scientists and regulators confronted a profound ethical question: should medicine move fast enough to save a single child? For geneticist Vanessa Almendro-Navarro, PhD, KJ’s case represented both an urgent humanitarian mission and a glimpse into the future of personalized medicine. In this interview, she explains how her team created a bespoke gene-editing therapy for KJ, what it reveals about the rise of one-patient medicines, and how unprecedented collaboration is reshaping the boundaries of science and ethics.


Produced and hosted by Jonathan D. Grinstein, PhD

Audio mixed and mastered by David Mosely

Brought to you by Inside Precision Medicine (SAGE Publishing)


Hosted on Acast. See acast.com/privacy for more information.

]]> Shana Kelley: Instrumented Tissues for Monitoring Human Body In Real-Time Shana Kelley: Instrumented Tissues for Monitoring Human Body In Real-Time Wed, 24 Sep 2025 07:01:00 GMT 45:39 68d2c52640bbaff2b9e227c7 false https://shows.acast.com/behind-the-breakthroughs-by-inside-precision-medicine/episodes/shana-kelley 68d2c52640bbaff2b9e227c7 67105af848726944170ab1fe shana-kelley Director at CZ Biohub Chicago, Professor at Northwestern University full 26 Shana Kelley, PhD, embraces bold, science-fiction-like challenges, such as developing real-time technologies to monitor immune activity—work that demands cross-disciplinary expertise, flexible funding, and visionary leadership. As a Professor at Northwestern University and President of the Chan Zuckerberg Biohub Chicago, she advances “instrumented tissues” to precisely measure biological processes, sharing her passion and insights on innovation in this episode of Behind the Breakthroughs.


Produced and hosted by Jonathan D. Grinstein, PhD

Audio mixed and mastered by David Mosely

Brought to you by Inside Precision Medicine (SAGE Publishing)

Hosted on Acast. See acast.com/privacy for more information.

]]> Shana Kelley, PhD, embraces bold, science-fiction-like challenges, such as developing real-time technologies to monitor immune activity—work that demands cross-disciplinary expertise, flexible funding, and visionary leadership. As a Professor at Northwestern University and President of the Chan Zuckerberg Biohub Chicago, she advances “instrumented tissues” to precisely measure biological processes, sharing her passion and insights on innovation in this episode of Behind the Breakthroughs.


Produced and hosted by Jonathan D. Grinstein, PhD

Audio mixed and mastered by David Mosely

Brought to you by Inside Precision Medicine (SAGE Publishing)

Hosted on Acast. See acast.com/privacy for more information.

]]> Mara Aspinall: Taking Diagnostics From Pitch to Patient Mara Aspinall: Taking Diagnostics From Pitch to Patient Wed, 03 Sep 2025 07:01:00 GMT 54:30 68b72b02a742b7c846e776ae false https://shows.acast.com/behind-the-breakthroughs-by-inside-precision-medicine/episodes/mara-aspinall 68b72b02a742b7c846e776ae 67105af848726944170ab1fe mara-aspinall Partner at Illumina Ventures full 25 Mara Aspinall has long been a leader in precision medicine, championing diagnostics as vital to better treatments and saving lives. She built Genzyme Genetics into the nation’s top testing business, later acquired by LabCorp for $1 billion, and led Ventana (now Roche Tissue Diagnostics) in pioneering companion diagnostics. As co-founder of BlueStone Venture Partners and partner at Illumina Ventures, she continues shaping the field. She also publishes the Diagnostics Year in Review, serves on multiple boards, and co-founded ASU’s School of Biomedical Diagnostics. This episode explores both her vision for testing and her journey to becoming a transformative leader.


Produced and hosted by Jonathan D. Grinstein, PhD

Audio mixed and mastered by David Mosely

Brought to you by Inside Precision Medicine (SAGE Publishing)

Hosted on Acast. See acast.com/privacy for more information.

]]> Mara Aspinall has long been a leader in precision medicine, championing diagnostics as vital to better treatments and saving lives. She built Genzyme Genetics into the nation’s top testing business, later acquired by LabCorp for $1 billion, and led Ventana (now Roche Tissue Diagnostics) in pioneering companion diagnostics. As co-founder of BlueStone Venture Partners and partner at Illumina Ventures, she continues shaping the field. She also publishes the Diagnostics Year in Review, serves on multiple boards, and co-founded ASU’s School of Biomedical Diagnostics. This episode explores both her vision for testing and her journey to becoming a transformative leader.


Produced and hosted by Jonathan D. Grinstein, PhD

Audio mixed and mastered by David Mosely

Brought to you by Inside Precision Medicine (SAGE Publishing)

Hosted on Acast. See acast.com/privacy for more information.

]]> David Liu: Performing Chemistry on DNA to Unlock Personalized Gene Editing David Liu: Performing Chemistry on DNA to Unlock Personalized Gene Editing Wed, 20 Aug 2025 07:00:00 GMT 55:54 68a4dffc457a24bb9581e226 false https://shows.acast.com/behind-the-breakthroughs-by-inside-precision-medicine/episodes/david-liu-performing-chemistry-on-dna-to-unlock-personalized 68a4dffc457a24bb9581e226 67105af848726944170ab1fe david-liu-performing-chemistry-on-dna-to-unlock-personalized Professor at Harvard University and the Broad Institute, co-founder of Beam Therapeutics and Prime Medcine full 24 David R. Liu, PhD, Harvard and Broad Institute professor, invented base and prime editing—gene editing tools now in 20+ clinical trials with early wins against sickle cell, leukemia, and more. Founder of Editas, Beam, and Prime Medicine, and winner of the 2025 Breakthrough Prize, Liu joins Behind The Breakthroughs to share how chemistry and evolution are driving the next wave of medicine.


Produced and hosted by Jonathan D. Grinstein, PhD

Audio mixed and mastered by David Mosely

Brought to you by Inside Precision Medicine (SAGE Publishing)

Hosted on Acast. See acast.com/privacy for more information.

]]> David R. Liu, PhD, Harvard and Broad Institute professor, invented base and prime editing—gene editing tools now in 20+ clinical trials with early wins against sickle cell, leukemia, and more. Founder of Editas, Beam, and Prime Medicine, and winner of the 2025 Breakthrough Prize, Liu joins Behind The Breakthroughs to share how chemistry and evolution are driving the next wave of medicine.


Produced and hosted by Jonathan D. Grinstein, PhD

Audio mixed and mastered by David Mosely

Brought to you by Inside Precision Medicine (SAGE Publishing)

Hosted on Acast. See acast.com/privacy for more information.

]]> Janice Chen: Unleashing CRISPR’s Clinical and Diagnostic Potential Janice Chen: Unleashing CRISPR’s Clinical and Diagnostic Potential Wed, 06 Aug 2025 07:00:00 GMT 41:22 6892a243d741d9fdcf8f75f3 false https://shows.acast.com/behind-the-breakthroughs-by-inside-precision-medicine/episodes/gonna-be-500-miles-unleashing-crisprs-clinical-and-diagnosti 6892a243d741d9fdcf8f75f3 67105af848726944170ab1fe gonna-be-500-miles-unleashing-crisprs-clinical-and-diagnosti Co-founder/CTO of Mammoth Biosciences full 23 Janice Chen, PhD, helped transform CRISPR from a lab discovery into a life-saving tool. As co-founder of Mammoth Biosciences with Jennifer Doudna, Trevor Martin, and Lucas Harrington, she’s driven efforts to harness CRISPR for human health and diagnostics. On Behind the Breakthroughs, Chen shares how she’s turning a once-theoretical gene editor into a medical revolution.


Produced and hosted by Jonathan D. Grinstein, PhD


Audio mixed and mastered by David Mosely


Brought to you by Inside Precision Medicine (SAGE Publishing)

Hosted on Acast. See acast.com/privacy for more information.

]]> Janice Chen, PhD, helped transform CRISPR from a lab discovery into a life-saving tool. As co-founder of Mammoth Biosciences with Jennifer Doudna, Trevor Martin, and Lucas Harrington, she’s driven efforts to harness CRISPR for human health and diagnostics. On Behind the Breakthroughs, Chen shares how she’s turning a once-theoretical gene editor into a medical revolution.


Produced and hosted by Jonathan D. Grinstein, PhD


Audio mixed and mastered by David Mosely


Brought to you by Inside Precision Medicine (SAGE Publishing)

Hosted on Acast. See acast.com/privacy for more information.

]]> Amber Salzman: Epigenetic Editing Aims to Refine Personalized Genetic Medicine Amber Salzman: Epigenetic Editing Aims to Refine Personalized Genetic Medicine Wed, 23 Jul 2025 07:00:00 GMT 40:57 688055b9498abee416ef990a false https://shows.acast.com/behind-the-breakthroughs-by-inside-precision-medicine/episodes/uncut-gems-epigenetic-editing-aims-to-refine-personalized-ge 688055b9498abee416ef990a 67105af848726944170ab1fe uncut-gems-epigenetic-editing-aims-to-refine-personalized-ge CEO of Epicrispr full 22 With recent safety setbacks in gene therapy underscoring the risks of genetic medicine, Amber Salzman, PhD, is charting a different course. After 25 years in big pharma, she now leads Epicrispr, where their Gene Expression Modulation System (GEMS) fine-tunes gene activity to tackle diseases too complex for traditional gene replacement, including Duchenne muscular dystrophy. On Behind the Breakthroughs, Salzman shares how epigenomic modulation could open new frontiers in treatment.


Produced and hosted by Jonathan D. Grinstein, PhD


Audio mixed and mastered by David Mosely


Brought to you by Inside Precision Medicine (SAGE Publishing)

Hosted on Acast. See acast.com/privacy for more information.

]]> With recent safety setbacks in gene therapy underscoring the risks of genetic medicine, Amber Salzman, PhD, is charting a different course. After 25 years in big pharma, she now leads Epicrispr, where their Gene Expression Modulation System (GEMS) fine-tunes gene activity to tackle diseases too complex for traditional gene replacement, including Duchenne muscular dystrophy. On Behind the Breakthroughs, Salzman shares how epigenomic modulation could open new frontiers in treatment.


Produced and hosted by Jonathan D. Grinstein, PhD


Audio mixed and mastered by David Mosely


Brought to you by Inside Precision Medicine (SAGE Publishing)

Hosted on Acast. See acast.com/privacy for more information.

]]> Mike Previte: Predicting Biology with Spatiotemporal Multiomics Mike Previte: Predicting Biology with Spatiotemporal Multiomics Wed, 09 Jul 2025 07:00:00 GMT 40:16 686d99a3e52066772f48f1b5 false https://shows.acast.com/behind-the-breakthroughs-by-inside-precision-medicine/episodes/more-than-a-feeling-predicting-biology-in-with-spatiotempora 686d99a3e52066772f48f1b5 67105af848726944170ab1fe more-than-a-feeling-predicting-biology-in-with-spatiotempora Co-founder/CTO of Element Biosciences full 21 Think Good Will Hunting—but in biology. Mike Previte, PhD, once at Illumina and now CTO and co-founder of Element Biosciences, is building tools to move beyond DNA and RNA sequencing toward a true 5D view of life. On Behind the Breakthroughs, he explains how technologies like AVITI 24 could unlock predictive precision medicine by revealing how cells behave across time and space.


Produced and hosted by Jonathan D. Grinstein, PhD


Audio mixed and mastered by David Mosely


Brought to you by Inside Precision Medicine (SAGE Publishing)

Hosted on Acast. See acast.com/privacy for more information.

]]> Think Good Will Hunting—but in biology. Mike Previte, PhD, once at Illumina and now CTO and co-founder of Element Biosciences, is building tools to move beyond DNA and RNA sequencing toward a true 5D view of life. On Behind the Breakthroughs, he explains how technologies like AVITI 24 could unlock predictive precision medicine by revealing how cells behave across time and space.


Produced and hosted by Jonathan D. Grinstein, PhD


Audio mixed and mastered by David Mosely


Brought to you by Inside Precision Medicine (SAGE Publishing)

Hosted on Acast. See acast.com/privacy for more information.

]]> Hervé Affagard: Creating Microbiomes to Fight Cancer, ALS, and More Hervé Affagard: Creating Microbiomes to Fight Cancer, ALS, and More Wed, 25 Jun 2025 07:00:00 GMT 35:11 6853626768b0c25e384ad536 false https://shows.acast.com/behind-the-breakthroughs-by-inside-precision-medicine/episodes/just-the-two-of-us-creating-microbiomes-to-fight-cancer-als 6853626768b0c25e384ad536 67105af848726944170ab1fe just-the-two-of-us-creating-microbiomes-to-fight-cancer-als Co-founder/CEO of MaaT Pharma full 20 Hervé Affagard, CEO and co-founder of MaaT Pharma, traded industrial engineering for medicine after cancer struck his family. Now, he’s pioneering microbiome-based therapies to restore balance in the gut, boost immunity, and tackle diseases from graft-versus-host to cancer itself. On Behind the Breakthroughs, Hervé shares how reimagining our inner ecosystem could transform treatment.

Want me to make this one lean even harder into the industrial-to-biotech transformation angle for extra contrast?


Produced and hosted by Jonathan D. Grinstein, PhD


Audio mixed and mastered by David Mosely


Brought to you by Inside Precision Medicine (SAGE Publishing)

Hosted on Acast. See acast.com/privacy for more information.

]]> Hervé Affagard, CEO and co-founder of MaaT Pharma, traded industrial engineering for medicine after cancer struck his family. Now, he’s pioneering microbiome-based therapies to restore balance in the gut, boost immunity, and tackle diseases from graft-versus-host to cancer itself. On Behind the Breakthroughs, Hervé shares how reimagining our inner ecosystem could transform treatment.

Want me to make this one lean even harder into the industrial-to-biotech transformation angle for extra contrast?


Produced and hosted by Jonathan D. Grinstein, PhD


Audio mixed and mastered by David Mosely


Brought to you by Inside Precision Medicine (SAGE Publishing)

Hosted on Acast. See acast.com/privacy for more information.

]]> Michelle Werner: Engineered tRNAs Offer Universal Solutions to Stop Codon Diseases Michelle Werner: Engineered tRNAs Offer Universal Solutions to Stop Codon Diseases Wed, 11 Jun 2025 07:00:00 GMT 38:21 684860e4d911dedd6567d86a false https://shows.acast.com/behind-the-breakthroughs-by-inside-precision-medicine/episodes/nonsense-engineered-trnas-offer-universal-solutions-to-stop- 684860e4d911dedd6567d86a 67105af848726944170ab1fe nonsense-engineered-trnas-offer-universal-solutions-to-stop- CEO of Alltrna and CEO/Partner at Flagship Pioneering full 19 When Michelle Werner, PhD, learned her son Caffrey had Duchenne muscular dystrophy, she left big pharma to lead Alltrna—a Flagship Pioneering company engineering tRNAs to tackle rare diseases with no treatments. On Behind the Breakthroughs, Werner shares her journey as both mother and CEO, and how Alltrna’s approach could unlock therapies for thousands of conditions caused by nonsense mutations.


Produced and hosted by Jonathan D. Grinstein, PhD


Audio mixed and mastered by David Mosely


Brought to you by Inside Precision Medicine (SAGE Publishing)

Hosted on Acast. See acast.com/privacy for more information.

]]> When Michelle Werner, PhD, learned her son Caffrey had Duchenne muscular dystrophy, she left big pharma to lead Alltrna—a Flagship Pioneering company engineering tRNAs to tackle rare diseases with no treatments. On Behind the Breakthroughs, Werner shares her journey as both mother and CEO, and how Alltrna’s approach could unlock therapies for thousands of conditions caused by nonsense mutations.


Produced and hosted by Jonathan D. Grinstein, PhD


Audio mixed and mastered by David Mosely


Brought to you by Inside Precision Medicine (SAGE Publishing)

Hosted on Acast. See acast.com/privacy for more information.

]]> Cassie Hajek: Population Genomic Screens Need More Than Pathogenic Variants Cassie Hajek: Population Genomic Screens Need More Than Pathogenic Variants Wed, 28 May 2025 07:00:00 GMT 38:07 6830eb4be57506ea970c0e57 false https://shows.acast.com/behind-the-breakthroughs-by-inside-precision-medicine/episodes/to-maximize-population-genetic-screening-pathogenic-variants 6830eb4be57506ea970c0e57 67105af848726944170ab1fe to-maximize-population-genetic-screening-pathogenic-variants Medical Affairs Director at Helix full 18 Public health is greatly benefiting from population genomics screening, as it provides patients with risk education and treatment for symptoms of life-threatening diseases that they would not have been aware of through routine checkups. So, why hasn't population genomic screening realized its full potential? As an internist geneticist and Medical Affairs Director at Helix, this issue became all the more real for Cassie Hajek, MD, when she was diagnosed with breast cancer that evaded existing genetic testing procedures. In this earnest episode, Hajek shares how her experiences as both a cancer patient and a practitioner have helped her identify and build towards overcoming some of the barriers to maximizing population genomic screening for preventive medicine.


Produced and hosted by Jonathan D. Grinstein, PhD


Audio mixed and mastered by David Mosely


Brought to you by Inside Precision Medicine (SAGE Publishing)

Hosted on Acast. See acast.com/privacy for more information.

]]> Public health is greatly benefiting from population genomics screening, as it provides patients with risk education and treatment for symptoms of life-threatening diseases that they would not have been aware of through routine checkups. So, why hasn't population genomic screening realized its full potential? As an internist geneticist and Medical Affairs Director at Helix, this issue became all the more real for Cassie Hajek, MD, when she was diagnosed with breast cancer that evaded existing genetic testing procedures. In this earnest episode, Hajek shares how her experiences as both a cancer patient and a practitioner have helped her identify and build towards overcoming some of the barriers to maximizing population genomic screening for preventive medicine.


Produced and hosted by Jonathan D. Grinstein, PhD


Audio mixed and mastered by David Mosely


Brought to you by Inside Precision Medicine (SAGE Publishing)

Hosted on Acast. See acast.com/privacy for more information.

]]> Patrick Hsu, Serge Saxonov, and Gilad Almogy: Creating the Virtual Cell Patrick Hsu, Serge Saxonov, and Gilad Almogy: Creating the Virtual Cell Wed, 14 May 2025 07:00:00 GMT 30:02 682374b114bdee61417837d3 false https://shows.acast.com/behind-the-breakthroughs-by-inside-precision-medicine/episodes/goodbye-guess-and-check-hello-virtual-cell 682374b114bdee61417837d3 67105af848726944170ab1fe goodbye-guess-and-check-hello-virtual-cell Hsu, Co-founder of Arc Institute | Saxonov, Co-founder/CEO of 10x Genomics | Almogy, Co-founder/CEO of Ultima Genomics full 17 Three biotech trailblazers—Patrick Hsu (co-founder of the Arc Institute), Serge Saxonov (co-founder and CEO of 10x Genomics), and Gilad Almogy (co-founder and CEO of Ultima Genomics)—join forces to discuss their groundbreaking collaboration on the virtual cell. This ambitious project leverages advanced AI and cutting-edge genomic technologies to model and predict cellular behavior, a leap forward in understanding complex biological systems. The trio dives deep into their shared vision, explaining how their partnership is redefining scientific research and pushing the boundaries of what’s possible in drug discovery and precision medicine.


Produced and hosted by Jonathan D. Grinstein, PhD


Audio mixed and mastered by David Mosely


Brought to you by Inside Precision Medicine (SAGE Publishing)

Hosted on Acast. See acast.com/privacy for more information.

]]> Three biotech trailblazers—Patrick Hsu (co-founder of the Arc Institute), Serge Saxonov (co-founder and CEO of 10x Genomics), and Gilad Almogy (co-founder and CEO of Ultima Genomics)—join forces to discuss their groundbreaking collaboration on the virtual cell. This ambitious project leverages advanced AI and cutting-edge genomic technologies to model and predict cellular behavior, a leap forward in understanding complex biological systems. The trio dives deep into their shared vision, explaining how their partnership is redefining scientific research and pushing the boundaries of what’s possible in drug discovery and precision medicine.


Produced and hosted by Jonathan D. Grinstein, PhD


Audio mixed and mastered by David Mosely


Brought to you by Inside Precision Medicine (SAGE Publishing)

Hosted on Acast. See acast.com/privacy for more information.

]]> Kate Sasser: How Lab-in-the-loop Turns Patient Data Into Patient Care Kate Sasser: How Lab-in-the-loop Turns Patient Data Into Patient Care Wed, 30 Apr 2025 07:00:00 GMT 35:55 6810f8439704d99f8410f9a2 false https://shows.acast.com/behind-the-breakthroughs-by-inside-precision-medicine/episodes/operation-oroborous-how-lab-in-the-loop-turns-patient-data-i 6810f8439704d99f8410f9a2 67105af848726944170ab1fe operation-oroborous-how-lab-in-the-loop-turns-patient-data-i CSO at Tempus full 16 For years, Tempus operated in mystery—its website sparse on details while headlines announced massive funding and high-profile partnerships. The claim? AI-enabled solutions for personalized healthcare. Intrigued, I sought answers. In this episode, Kate Sasser, PhD, Chief Scientific Officer at Tempus, shared insights into how the company uses AI to analyze unstructured clinical data to develop patient-derived organoid models for therapeutic refinement. Most exciting is their vision of an interconnected “lab-in-a-loop” system—a cycle of real-world data, biological modeling, and AI analysis.


Produced and hosted by Jonathan D. Grinstein, PhD


Audio mixed and mastered by David Mosely


Brought to you by Inside Precision Medicine (SAGE Publishing)

Hosted on Acast. See acast.com/privacy for more information.

]]> For years, Tempus operated in mystery—its website sparse on details while headlines announced massive funding and high-profile partnerships. The claim? AI-enabled solutions for personalized healthcare. Intrigued, I sought answers. In this episode, Kate Sasser, PhD, Chief Scientific Officer at Tempus, shared insights into how the company uses AI to analyze unstructured clinical data to develop patient-derived organoid models for therapeutic refinement. Most exciting is their vision of an interconnected “lab-in-a-loop” system—a cycle of real-world data, biological modeling, and AI analysis.


Produced and hosted by Jonathan D. Grinstein, PhD


Audio mixed and mastered by David Mosely


Brought to you by Inside Precision Medicine (SAGE Publishing)

Hosted on Acast. See acast.com/privacy for more information.

]]> Kian Sadeghi: Is Personalized Genomics Undergoing a Direct-to-Consumer Renaissance? Kian Sadeghi: Is Personalized Genomics Undergoing a Direct-to-Consumer Renaissance? Wed, 16 Apr 2025 07:01:00 GMT 44:34 67feb26e66d94e7a62a099ac false https://shows.acast.com/behind-the-breakthroughs-by-inside-precision-medicine/episodes/is-personalized-genomics-undergoing-a-direct-to-consumer-ren 67feb26e66d94e7a62a099ac 67105af848726944170ab1fe is-personalized-genomics-undergoing-a-direct-to-consumer-ren Founder/CEO at Nucleus Genomics full 15 At just 25, UPenn dropout Kian Sadeghi is betting big on personalized genomics. As founder of Nucleus Genomics, he’s offering affordable whole-genome sequencing direct to consumers and rethinking how patients, clinicians, and insurers engage with genetic data. On Behind the Breakthroughs, Sadeghi unpacks the fall of 23andMe, the rise of patient agency, and why he thinks genomics needs its own Bill Gates.


Stay up to date with the latest episodes of Behind the Breakthroughs by subscribing to the IPM eNewsletter here.


Produced by Bill Levine

Hosted by Jonathan D. Grinstein

Audio mixed and mastered by Jason Mack

Music provided by Artem Hramushkin

Hosted on Acast. See acast.com/privacy for more information.

]]> At just 25, UPenn dropout Kian Sadeghi is betting big on personalized genomics. As founder of Nucleus Genomics, he’s offering affordable whole-genome sequencing direct to consumers and rethinking how patients, clinicians, and insurers engage with genetic data. On Behind the Breakthroughs, Sadeghi unpacks the fall of 23andMe, the rise of patient agency, and why he thinks genomics needs its own Bill Gates.


Stay up to date with the latest episodes of Behind the Breakthroughs by subscribing to the IPM eNewsletter here.


Produced by Bill Levine

Hosted by Jonathan D. Grinstein

Audio mixed and mastered by Jason Mack

Music provided by Artem Hramushkin

Hosted on Acast. See acast.com/privacy for more information.

]]> Carlos D. Bustamante: Latin American Diversity’s Genetic Potential Carlos D. Bustamante: Latin American Diversity’s Genetic Potential Wed, 02 Apr 2025 07:00:00 GMT 50:34 67ec5961506c6c628cc61d23 false https://shows.acast.com/behind-the-breakthroughs-by-inside-precision-medicine/episodes/from-medellin-to-the-caribbean-mapping-genetic-diversity-for 67ec5961506c6c628cc61d23 67105af848726944170ab1fe from-medellin-to-the-caribbean-mapping-genetic-diversity-for Founder/CEO of Galatea Bio full 14 Imagine a future where your ancestry not only tells a story about your past but also holds the key to your health. That's the vision drives Carlos D. Bustamante, PhD, population geneticist and founder of Galatea Bio, as he embarks on an ambitious mission: building a biobank of 10 million genomes to transform drug development and healthcare across Latin America. With thousands of founder populations scattered across the region—from the valleys of Medellín to the islands of the Caribbean—Latin America is a goldmine of genetic diversity. Yet, until now, it has been largely overlooked in genomic research. In this Behind the Breakthroughs episode, Bustamante explains why mapping this diversity can uncover genetic insights that will lead to better treatments for diseases that disproportionately affect these communities.


Stay up to date with the latest episodes of Behind the Breakthroughs by subscribing to the IPM eNewsletter here.


Produced by Bill Levine

Hosted by Jonathan D. Grinstein

Music provided by Artem Hramushkin

Audio mixed and mastered by Jason Mack

Hosted on Acast. See acast.com/privacy for more information.

]]> Imagine a future where your ancestry not only tells a story about your past but also holds the key to your health. That's the vision drives Carlos D. Bustamante, PhD, population geneticist and founder of Galatea Bio, as he embarks on an ambitious mission: building a biobank of 10 million genomes to transform drug development and healthcare across Latin America. With thousands of founder populations scattered across the region—from the valleys of Medellín to the islands of the Caribbean—Latin America is a goldmine of genetic diversity. Yet, until now, it has been largely overlooked in genomic research. In this Behind the Breakthroughs episode, Bustamante explains why mapping this diversity can uncover genetic insights that will lead to better treatments for diseases that disproportionately affect these communities.


Stay up to date with the latest episodes of Behind the Breakthroughs by subscribing to the IPM eNewsletter here.


Produced by Bill Levine

Hosted by Jonathan D. Grinstein

Music provided by Artem Hramushkin

Audio mixed and mastered by Jason Mack

Hosted on Acast. See acast.com/privacy for more information.

]]> Josh Denny: The Future of Precision Public Health Josh Denny: The Future of Precision Public Health Wed, 19 Mar 2025 17:07:18 GMT 39:44 67da0a8113f133b29d2d4382 false https://shows.acast.com/behind-the-breakthroughs-by-inside-precision-medicine/episodes/zip-codes-and-genetic-codes-ai-glasses-and-smart-toilets-and 67da0a8113f133b29d2d4382 67105af848726944170ab1fe zip-codes-and-genetic-codes-ai-glasses-and-smart-toilets-and full 13 Josh Denny, MD, turned a family tragedy with cystic fibrosis into a lifelong mission to transform medicine. Now CEO of the NIH’s All of Us Research Program, he’s leading one of the largest precision medicine efforts in history—850,000 participants strong with 400,000 genomic profiles and counting. On Behind the Breakthroughs, Denny shares how this unprecedented dataset could rewrite the future of healthcare, from rare disease to everyday care.


Stay up to date with the latest episodes of Behind the Breakthroughs by subscribing to the IPM eNewsletter here.


Produced by Bill Levine

Hosted by Jonathan D. Grinstein

Music provided by Artem Hramushkin

Audio mixed and mastered by Jason Mack

Hosted on Acast. See acast.com/privacy for more information.

]]> Josh Denny, MD, turned a family tragedy with cystic fibrosis into a lifelong mission to transform medicine. Now CEO of the NIH’s All of Us Research Program, he’s leading one of the largest precision medicine efforts in history—850,000 participants strong with 400,000 genomic profiles and counting. On Behind the Breakthroughs, Denny shares how this unprecedented dataset could rewrite the future of healthcare, from rare disease to everyday care.


Stay up to date with the latest episodes of Behind the Breakthroughs by subscribing to the IPM eNewsletter here.


Produced by Bill Levine

Hosted by Jonathan D. Grinstein

Music provided by Artem Hramushkin

Audio mixed and mastered by Jason Mack

Hosted on Acast. See acast.com/privacy for more information.

]]> Uli Stilz: Conquering Complex Diseases Affecting Billions with Precision Medicine Uli Stilz: Conquering Complex Diseases Affecting Billions with Precision Medicine Wed, 05 Mar 2025 08:01:00 GMT 34:01 67c7de87ece4993ac7fd72fb false https://shows.acast.com/behind-the-breakthroughs-by-inside-precision-medicine/episodes/conquering-complex-diseases-with-precision-medicine 67c7de87ece4993ac7fd72fb 67105af848726944170ab1fe conquering-complex-diseases-with-precision-medicine full 12 The sage-like Uli Stilz, PhD, Vice President of Novo Nordisk, provides insight into the inner workings of Novo Nordisk’s Bio Innovation Hub, which he founded in Boston, to tackle complex, multifactorial diseases that impact billions of people, such as diabetes and cardiometabolic diseases.


Stay up to date with the latest episodes of Behind the Breakthroughs by subscribing to the IPM eNewsletter here.


Produced by Bill Levine

Hosted by Jonathan D. Grinstein

Music provided by Artem Hramushkin

Audio mixed and mastered by Jason Mack

Hosted on Acast. See acast.com/privacy for more information.

]]> The sage-like Uli Stilz, PhD, Vice President of Novo Nordisk, provides insight into the inner workings of Novo Nordisk’s Bio Innovation Hub, which he founded in Boston, to tackle complex, multifactorial diseases that impact billions of people, such as diabetes and cardiometabolic diseases.


Stay up to date with the latest episodes of Behind the Breakthroughs by subscribing to the IPM eNewsletter here.


Produced by Bill Levine

Hosted by Jonathan D. Grinstein

Music provided by Artem Hramushkin

Audio mixed and mastered by Jason Mack

Hosted on Acast. See acast.com/privacy for more information.

]]> Tomasz (Tom) Beer: Detecting Cancer Before Symptoms? MCED Leads the Way Tomasz (Tom) Beer: Detecting Cancer Before Symptoms? MCED Leads the Way Wed, 19 Feb 2025 08:01:00 GMT 26:33 67b56dc8d7f65bb045e00a61 false https://shows.acast.com/behind-the-breakthroughs-by-inside-precision-medicine/episodes/detecting-cancer-before-symptoms-multicancer-early-detection 67b56dc8d7f65bb045e00a61 67105af848726944170ab1fe detecting-cancer-before-symptoms-multicancer-early-detection Vice President and Chief Medical Officer for Multi-Cancer Early Detection at Exact Sciences full 11 Despite advances in screening, only one in six U.S. cancers is detected early. Tomasz (Tom) Beer, MD, left most of his clinical practice to join Exact Sciences and push the frontier with blood-based multicancer early detection (MCED) tests. On Behind the Breakthroughs, Beer explains how these tests could transform cancer screening and catch disease before it’s too late.


Stay up to date with the latest episodes of Behind the Breakthroughs by subscribing to the IPM eNewsletter here.


Produced by Bill Levine

Hosted by Jonathan D. Grinstein

Music provided by Artem Hramushkin

Audio mixed and mastered by Jason Mack

Hosted on Acast. See acast.com/privacy for more information.

]]> Despite advances in screening, only one in six U.S. cancers is detected early. Tomasz (Tom) Beer, MD, left most of his clinical practice to join Exact Sciences and push the frontier with blood-based multicancer early detection (MCED) tests. On Behind the Breakthroughs, Beer explains how these tests could transform cancer screening and catch disease before it’s too late.


Stay up to date with the latest episodes of Behind the Breakthroughs by subscribing to the IPM eNewsletter here.


Produced by Bill Levine

Hosted by Jonathan D. Grinstein

Music provided by Artem Hramushkin

Audio mixed and mastered by Jason Mack

Hosted on Acast. See acast.com/privacy for more information.

]]> Katy Rezvani: Allogeneic NK Cells Are Coming to Beat Cancer at a Clinic Near You Katy Rezvani: Allogeneic NK Cells Are Coming to Beat Cancer at a Clinic Near You Wed, 05 Feb 2025 08:01:00 GMT 39:54 67a2a3410ef429ce22b78741 false https://shows.acast.com/behind-the-breakthroughs-by-inside-precision-medicine/episodes/allogeneic-nk-cells-are-coming-to-beat-cancer-at-to-a-clinic 67a2a3410ef429ce22b78741 67105af848726944170ab1fe allogeneic-nk-cells-are-coming-to-beat-cancer-at-to-a-clinic full 10 Katy Rezvani, MD, PhD, turned her fascination with immunology into a career engineering allogeneic immune cell therapies. On Behind the Breakthroughs, Rezvani explains why NK cells—unlike T cells—hold promise for safer, more accessible cancer treatments, and how her work at MD Anderson is shaping the future of cell therapy.


Stay up to date with the latest episodes of Behind the Breakthroughs by subscribing to the IPM eNewsletter here.


Produced by Bill Levine

Hosted by Jonathan D. Grinstein, PhD

Music provided by Artem Hramushkin

Audio mixed and mastered by Jason Mack

Hosted on Acast. See acast.com/privacy for more information.

]]> Katy Rezvani, MD, PhD, turned her fascination with immunology into a career engineering allogeneic immune cell therapies. On Behind the Breakthroughs, Rezvani explains why NK cells—unlike T cells—hold promise for safer, more accessible cancer treatments, and how her work at MD Anderson is shaping the future of cell therapy.


Stay up to date with the latest episodes of Behind the Breakthroughs by subscribing to the IPM eNewsletter here.


Produced by Bill Levine

Hosted by Jonathan D. Grinstein, PhD

Music provided by Artem Hramushkin

Audio mixed and mastered by Jason Mack

Hosted on Acast. See acast.com/privacy for more information.

]]> Toby Ferguson: From Bloodstream to Brain: Accessing the Neurogenetic Medicine Revolution Toby Ferguson: From Bloodstream to Brain: Accessing the Neurogenetic Medicine Revolution Wed, 22 Jan 2025 05:01:00 GMT 29:09 679058c71dc9bbb210cf3bc8 false https://shows.acast.com/behind-the-breakthroughs-by-inside-precision-medicine/episodes/clearing-the-blood-brain-barrier-for-accessible-genetic-medi 679058c71dc9bbb210cf3bc8 67105af848726944170ab1fe clearing-the-blood-brain-barrier-for-accessible-genetic-medi CMO of Voyager Therapeutics full 9 "Are we close to curing diseases like ALS and Alzheimer's?" In recent years, several academic and industry endeavors have given reason to be hopeful. Toby Ferguson, MD, PhD, is the Chief Medical Officer at Voyager Therapeutics, which develops genetic medicines and delivery tools to cross the blood-brain barrier (BBB). In this episode, Ferguson explains the current state of therapeutics for neurological and neurodegenerative diseases, challenges in delivering genetic medicines and other therapeutics to the nervous system, and Voyager's approach to overcoming the BBB.


Stay up to date with the latest episodes of Behind the Breakthroughs by subscribing to the IPM eNewsletter here.


Produced by Bill Levine

Hosted by Jonathan D. Grinstein

Music provided by Artem Hramushkin

Audio mixed and mastered by Jason Mack

Hosted on Acast. See acast.com/privacy for more information.

]]> "Are we close to curing diseases like ALS and Alzheimer's?" In recent years, several academic and industry endeavors have given reason to be hopeful. Toby Ferguson, MD, PhD, is the Chief Medical Officer at Voyager Therapeutics, which develops genetic medicines and delivery tools to cross the blood-brain barrier (BBB). In this episode, Ferguson explains the current state of therapeutics for neurological and neurodegenerative diseases, challenges in delivering genetic medicines and other therapeutics to the nervous system, and Voyager's approach to overcoming the BBB.


Stay up to date with the latest episodes of Behind the Breakthroughs by subscribing to the IPM eNewsletter here.


Produced by Bill Levine

Hosted by Jonathan D. Grinstein

Music provided by Artem Hramushkin

Audio mixed and mastered by Jason Mack

Hosted on Acast. See acast.com/privacy for more information.

]]> Tomi Pastinen: Treating All the Not-So-Rare “Rare Disease” Patients at Major Care Centers Tomi Pastinen: Treating All the Not-So-Rare “Rare Disease” Patients at Major Care Centers Wed, 08 Jan 2025 08:01:04 GMT 30:12 677d8c831f00b28b23c4a40c false https://shows.acast.com/behind-the-breakthroughs-by-inside-precision-medicine/episodes/treating-the-not-so-rare-rare-disease-patients-at-major-care 677d8c831f00b28b23c4a40c 67105af848726944170ab1fe treating-the-not-so-rare-rare-disease-patients-at-major-care full 8 Tomi Pastinen, MD, PhD, is transforming pediatric medicine through genomics. As Director at Children’s Mercy Kansas City, he’s pioneered pharmacogenetic testing and 5-nucleotide genomic sequencing, bringing precision medicine to children. On Behind the Breakthroughs, Pastinen discusses the promise—and challenges—of turning genetic diagnoses into real treatments, from rare inherited diseases to complex conditions like autism.


Stay up to date with the latest episodes of Behind the Breakthroughs by subscribing to the IPM eNewsletter here.


Produced by Bill Levine

Hosted by Jonathan D. Grinstein

Music provided by Artem Hramushkin

Audio mixed and mastered by Jason Mack

Hosted on Acast. See acast.com/privacy for more information.

]]> Tomi Pastinen, MD, PhD, is transforming pediatric medicine through genomics. As Director at Children’s Mercy Kansas City, he’s pioneered pharmacogenetic testing and 5-nucleotide genomic sequencing, bringing precision medicine to children. On Behind the Breakthroughs, Pastinen discusses the promise—and challenges—of turning genetic diagnoses into real treatments, from rare inherited diseases to complex conditions like autism.


Stay up to date with the latest episodes of Behind the Breakthroughs by subscribing to the IPM eNewsletter here.


Produced by Bill Levine

Hosted by Jonathan D. Grinstein

Music provided by Artem Hramushkin

Audio mixed and mastered by Jason Mack

Hosted on Acast. See acast.com/privacy for more information.

]]> Tom Whitehead: Not All Precision Medicine Heroes Wear Lab Coats Tom Whitehead: Not All Precision Medicine Heroes Wear Lab Coats Wed, 18 Dec 2024 05:01:21 GMT 31:15 6760823964b31a64799e11d0 false https://shows.acast.com/behind-the-breakthroughs-by-inside-precision-medicine/episodes/not-all-precision-medicine-heroes-wear-lab-coats 6760823964b31a64799e11d0 67105af848726944170ab1fe not-all-precision-medicine-heroes-wear-lab-coats Co-Founder of the Emily Whitehead Foundation full 7 Tom Whitehead, father of Emily Whitehead—the first pediatric CAR T patient—turned a harrowing journey into a mission to help families navigating life-threatening illness. On Behind the Breakthroughs, he shares the emotional story of Emily’s treatment and the challenges patients face when cutting-edge research intersects with real-world care.


This is the 2024 finale for Behind the Breakthroughs, and we will release our next episode on January 8, 2025.


Stay up to date with the latest episodes of Behind the Breakthroughs by subscribing to the IPM eNewsletter here.


Produced by Bill Levine

Hosted by Jonathan D. Grinstein

Music provided by Artem Hramushkin

Audio mixed and mastered by Jason Mack

Hosted on Acast. See acast.com/privacy for more information.

]]> Tom Whitehead, father of Emily Whitehead—the first pediatric CAR T patient—turned a harrowing journey into a mission to help families navigating life-threatening illness. On Behind the Breakthroughs, he shares the emotional story of Emily’s treatment and the challenges patients face when cutting-edge research intersects with real-world care.


This is the 2024 finale for Behind the Breakthroughs, and we will release our next episode on January 8, 2025.


Stay up to date with the latest episodes of Behind the Breakthroughs by subscribing to the IPM eNewsletter here.


Produced by Bill Levine

Hosted by Jonathan D. Grinstein

Music provided by Artem Hramushkin

Audio mixed and mastered by Jason Mack

Hosted on Acast. See acast.com/privacy for more information.

]]> Harry Clifford: Carrying Medicine Into the Post-Moore’s Law Era Harry Clifford: Carrying Medicine Into the Post-Moore’s Law Era Wed, 04 Dec 2024 04:43:36 GMT 26:38 674fdc808de4ab34dcc7bd3e false https://shows.acast.com/behind-the-breakthroughs-by-inside-precision-medicine/episodes/carrying-medicine-into-the-post-moores-law-era 674fdc808de4ab34dcc7bd3e 67105af848726944170ab1fe carrying-medicine-into-the-post-moores-law-era Digital Biology Lead at NVIDIA full 6 Harry Clifford, PhD, Digital Biology Lead at NVIDIA, discusses how the computer manufacturing and AI computing leader is building a technology platform to address data bottlenecks in drug development and healthcare to advance precision medicine.


Stay up to date with the latest episodes of Behind the Breakthroughs by subscribing to the IPM eNewsletter here.


Produced by Bill Levine

Hosted by Jonathan D. Grinstein

Music provided by Artem Hramushkin

Audio mixed and mastered by Jason Mack

Hosted on Acast. See acast.com/privacy for more information.

]]> Harry Clifford, PhD, Digital Biology Lead at NVIDIA, discusses how the computer manufacturing and AI computing leader is building a technology platform to address data bottlenecks in drug development and healthcare to advance precision medicine.


Stay up to date with the latest episodes of Behind the Breakthroughs by subscribing to the IPM eNewsletter here.


Produced by Bill Levine

Hosted by Jonathan D. Grinstein

Music provided by Artem Hramushkin

Audio mixed and mastered by Jason Mack

Hosted on Acast. See acast.com/privacy for more information.

]]> Michael Severino: Towards In Vivo Genome Editing of Humans Michael Severino: Towards In Vivo Genome Editing of Humans Thu, 21 Nov 2024 19:41:46 GMT 33:46 673eeb9ffc7e86ea70ede34f false https://shows.acast.com/behind-the-breakthroughs-by-inside-precision-medicine/episodes/towards-in-vivo-genome-editing-in-humans 673eeb9ffc7e86ea70ede34f 67105af848726944170ab1fe towards-in-vivo-genome-editing-in-humans CEO at Tessera Therapeutics full 5 Michael Severino, MD, discusses the approaches for developing "genome writers" at Tessera Therapeutics, where he joined as CEO in 2022, and the advantages of performing in vivo genome editing over ex vivo approaches. Severino explains where the company is in utilizing its genome writing platform to perform edits in vivo on its journey toward the clinic.


Stay up to date with the latest episodes of Behind the Breakthroughs by subscribing to the IPM eNewsletter here.


Produced by Bill Levine

Hosted by Jonathan D. Grinstein, PhD

Music provided by Artem Hramushkin

Audio mixed and mastered by Jason Mack


Hosted on Acast. See acast.com/privacy for more information.

]]> Michael Severino, MD, discusses the approaches for developing "genome writers" at Tessera Therapeutics, where he joined as CEO in 2022, and the advantages of performing in vivo genome editing over ex vivo approaches. Severino explains where the company is in utilizing its genome writing platform to perform edits in vivo on its journey toward the clinic.


Stay up to date with the latest episodes of Behind the Breakthroughs by subscribing to the IPM eNewsletter here.


Produced by Bill Levine

Hosted by Jonathan D. Grinstein, PhD

Music provided by Artem Hramushkin

Audio mixed and mastered by Jason Mack


Hosted on Acast. See acast.com/privacy for more information.

]]> Jane Gibson: AMP and Molecular Diagnostics’ Existential Crisis Jane Gibson: AMP and Molecular Diagnostics’ Existential Crisis Wed, 13 Nov 2024 17:49:33 GMT 27:04 6734e6aef3e242968539e162 false https://shows.acast.com/behind-the-breakthroughs-by-inside-precision-medicine/episodes/behind-the-breakthroughs-amp-and-molecular-diagnostics-exist 6734e6aef3e242968539e162 67105af848726944170ab1fe behind-the-breakthroughs-amp-and-molecular-diagnostics-exist Professor at the University of Central Florida and President of Association for Molecular Pathology (AMP) full 4 This special edition episode for the upcoming Association for Molecular Pathology (AMP) annual meeting in Vancouver, Jane Gibson, PhD, opens up the dialogue about how the evolving field of molecular pathology is taking on major challenges, including how the FDA’s ruling on laboratory developed tests (LDTs) is affecting clinical labs. Dr. Gibson is a Professor of Pathology at the University of Central Florida, Editor-in-chief of Genetic Testing and Molecular Biomarkers, and President Elect of AMP.


Stay up to date with the latest episodes of Behind the Breakthroughs by subscribing to the IPM eNewsletter here.


Produced by Bill Levine

Hosted by Jonathan D. Grinstein, PhD

Music provided by Artem Hramushkin

Audio mixed and mastered by Jason Mack

 

Hosted on Acast. See acast.com/privacy for more information.

]]> This special edition episode for the upcoming Association for Molecular Pathology (AMP) annual meeting in Vancouver, Jane Gibson, PhD, opens up the dialogue about how the evolving field of molecular pathology is taking on major challenges, including how the FDA’s ruling on laboratory developed tests (LDTs) is affecting clinical labs. Dr. Gibson is a Professor of Pathology at the University of Central Florida, Editor-in-chief of Genetic Testing and Molecular Biomarkers, and President Elect of AMP.


Stay up to date with the latest episodes of Behind the Breakthroughs by subscribing to the IPM eNewsletter here.


Produced by Bill Levine

Hosted by Jonathan D. Grinstein, PhD

Music provided by Artem Hramushkin

Audio mixed and mastered by Jason Mack

 

Hosted on Acast. See acast.com/privacy for more information.

]]> Helen Sabzevari: How to Turn $1,000,000 CAR Ts into “Real” Precision Medicines Helen Sabzevari: How to Turn $1,000,000 CAR Ts into “Real” Precision Medicines Wed, 30 Oct 2024 15:33:30 GMT 30:20 672251ca77f0e7cbfb98034c false https://shows.acast.com/behind-the-breakthroughs-by-inside-precision-medicine/episodes/how-to-turn-1000000-car-ts-into-real-medicines 672251ca77f0e7cbfb98034c 67105af848726944170ab1fe how-to-turn-1000000-car-ts-into-real-medicines President/CEO at Precigen full 3 Helen Sabzevari, PhD, President and CEO of Precigen, discusses the barriers to implementing cell and gene therapies that impede the accessibility and implementation of these precision medicines. Dr. Sabzevari also explains how key cell and gene therapy platforms and tools can provide safety measures, such as guardrails to cellular toxicity, and address cost by offering “off-the-shelf” efficient gene delivery vectors that can be used on-site, cutting out centralized manufacturing.


Stay up to date with the latest episodes of Behind the Breakthroughs by subscribing to the IPM eNewsletter here.


Produced by Bill Levine

Hosted by Jonathan D. Grinstein, PhD

Music provided by Artem Hramushkin

Audio mixed and mastered by Jason Mack

 

Hosted on Acast. See acast.com/privacy for more information.

]]> Helen Sabzevari, PhD, President and CEO of Precigen, discusses the barriers to implementing cell and gene therapies that impede the accessibility and implementation of these precision medicines. Dr. Sabzevari also explains how key cell and gene therapy platforms and tools can provide safety measures, such as guardrails to cellular toxicity, and address cost by offering “off-the-shelf” efficient gene delivery vectors that can be used on-site, cutting out centralized manufacturing.


Stay up to date with the latest episodes of Behind the Breakthroughs by subscribing to the IPM eNewsletter here.


Produced by Bill Levine

Hosted by Jonathan D. Grinstein, PhD

Music provided by Artem Hramushkin

Audio mixed and mastered by Jason Mack

 

Hosted on Acast. See acast.com/privacy for more information.

]]> Luca Quagliata: Weaving Genomic Profiling into Personalized Cancer Care Luca Quagliata: Weaving Genomic Profiling into Personalized Cancer Care Fri, 25 Oct 2024 14:30:32 GMT 16:33 671bab8822be238ac9640d1d false https://shows.acast.com/behind-the-breakthroughs-by-inside-precision-medicine/episodes/weaving-genomic-profiling-across-cancer-care 671bab8822be238ac9640d1d 67105af848726944170ab1fe weaving-genomic-profiling-across-cancer-care full 2

Luca Quagliata, PhD, global head of medical affairs for clinical NGS and oncology at Thermo Fisher Scientific, shares how his career has been intertwined with precision medicine, beginning with his time as a student in Italy during the early 2000s. Quagliata examines the significance of genomic profiling within the cancer care continuum, outlining the essential steps and touchpoints necessary to ensure the accessibility of personalized oncology treatment for all individuals.

 

Stay up to date with the latest episodes of Behind the Breakthroughs by subscribing to the IPM eNewsletter here.


7Q4XKpRvPIvPZPkK6RbZ


Produced by Bill Levine

Hosted by Jonathan D. Grinstein, PhD

Music provided by Artem Hramushkin

Audio mixed and mastered by Jason Mack

Hosted on Acast. See acast.com/privacy for more information.

]]>

Luca Quagliata, PhD, global head of medical affairs for clinical NGS and oncology at Thermo Fisher Scientific, shares how his career has been intertwined with precision medicine, beginning with his time as a student in Italy during the early 2000s. Quagliata examines the significance of genomic profiling within the cancer care continuum, outlining the essential steps and touchpoints necessary to ensure the accessibility of personalized oncology treatment for all individuals.

 

Stay up to date with the latest episodes of Behind the Breakthroughs by subscribing to the IPM eNewsletter here.


7Q4XKpRvPIvPZPkK6RbZ


Produced by Bill Levine

Hosted by Jonathan D. Grinstein, PhD

Music provided by Artem Hramushkin

Audio mixed and mastered by Jason Mack

Hosted on Acast. See acast.com/privacy for more information.

]]> Geoff Oxnard: The Tipping Point for Adopting Precision Medicine Geoff Oxnard: The Tipping Point for Adopting Precision Medicine Thu, 17 Oct 2024 00:40:36 GMT 34:41 67105d02b1e7b0e7e535b552 false https://shows.acast.com/behind-the-breakthroughs-by-inside-precision-medicine/episodes/the-tipping-point-for-adopting-precision-medicine 67105d02b1e7b0e7e535b552 67105af848726944170ab1fe the-tipping-point-for-adopting-precision-medicine VP at Eli Lilly and Faculty at Dana-Farber Cancer Institute and Harvard Medical School full 1 In the premiere episode of Behind the Breakthroughs, Geoff Oxnard, MD, VP of Clinical Development at Lilly and a Thoracic Oncologist at Boston Medical Center, shares his journey in precision medicine, beginning with his introduction to genetic testing as a Medical Oncology Fellow at Memorial Sloan-Kettering Cancer Center and as an academic researcher. Oxnard discusses how differences in impact and reach influenced his decision to move from academia to industry. He also explains how the adoption of precision testing in the United States is influenced by perspective rather than accessibility. This episode also covers flexible enrollment in clinical trials, adapting to patient perspectives on clinical research as care, the current state of precision medicine, particularly precision oncology, in the United States and elsewhere, and more.

 

Stay up to date with the latest episodes of Behind the Breakthroughs by subscribing to the IPM eNewsletter here.


Produced by Bill Levine

Hosted by Jonathan D. Grinstein, PhD

Music provided by Artem Hramushkin

Audio mixed and mastered by Jason Mack

Hosted on Acast. See acast.com/privacy for more information.

]]> In the premiere episode of Behind the Breakthroughs, Geoff Oxnard, MD, VP of Clinical Development at Lilly and a Thoracic Oncologist at Boston Medical Center, shares his journey in precision medicine, beginning with his introduction to genetic testing as a Medical Oncology Fellow at Memorial Sloan-Kettering Cancer Center and as an academic researcher. Oxnard discusses how differences in impact and reach influenced his decision to move from academia to industry. He also explains how the adoption of precision testing in the United States is influenced by perspective rather than accessibility. This episode also covers flexible enrollment in clinical trials, adapting to patient perspectives on clinical research as care, the current state of precision medicine, particularly precision oncology, in the United States and elsewhere, and more.

 

Stay up to date with the latest episodes of Behind the Breakthroughs by subscribing to the IPM eNewsletter here.


Produced by Bill Levine

Hosted by Jonathan D. Grinstein, PhD

Music provided by Artem Hramushkin

Audio mixed and mastered by Jason Mack

Hosted on Acast. See acast.com/privacy for more information.

]]>